All In Biotech

Drug Trial Radar · NCT07808151

Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer

A Phase 2, Open-Label, Multicenter, Randomized Trial Evaluating the Efficacy and Safety of Different Schedules of Neoadjuvant Pembrolizumab and Porustobart in Patients With Resectable pMMR/MSS Colon Cancer

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Sep 30, 2029

Study completion Sep 30, 2029

Sponsor

Lead sponsor
Solstice Oncology, Inc.Industry
Sponsor type
Industry
First posted
Sep 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if giving two medicines together, porustobart and pembrolizumab, before surgery can treat a common type of colon cancer called microsatellite stable (MSS) colon cancer in adults. This type of cancer can be removed with surgery and has not spread to other parts of the body. Both medicines work by helping the immune system fight cancer. The main questions this study wants to answer: How well do the medicines destroy the cancer before surgery? What side effects do participants have when taking the medicines? Researchers will compare two groups to see which treatment schedule works better and is safer. Both groups get pembrolizumab. One group gets one dose of porustobart (Day 1 only), and the other group gets two doses (Day 1 and Day 22). Participants will: Complete certain tests and procedures to make sure they are eligible Get the medicines through a vein on Day 1 and Day 22 then have surgery 6-9 weeks after starting treatment Return for checkups and tests every 6 months for up to 3 years after surgery

Conditions

  • Colon Cancer

Interventions

  • PembrolizumabDrug

    Administered to: Dose Schedule 1 - Porustobart + Pembrolizumab, Dose Schedule 2 - Porustobart + Pembrolizumab

  • PorustobartDrug

    Administered to: Dose Schedule 1 - Porustobart + Pembrolizumab, Dose Schedule 2 - Porustobart + Pembrolizumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Pathologic Response (MPR) rate by Blinded Independent Pathologic Review (BIPR)Time frame: Assessed from surgical resection specimen (surgery occurs Day 42-Day 63, i.e., approximately Week 6-Week 9 after first dose)

Locations

30 sites in 6 countries. Site status is shown where the registry gives one.

  • Investigator Site

    Los Angeles, California · Recruiting

  • Investigator Site

    Tampa, Florida · Not yet recruiting

  • Investigator Site

    Chicago, Illinois · Not yet recruiting

  • Investigator Site

    Baltimore, Maryland · Recruiting

  • Investigator Site

    Boston, Massachusetts · Not yet recruiting

  • Investigator Site

    New York, New York · Not yet recruiting

  • Investigator Site

    New York, New York · Not yet recruiting

  • Investigator Site

    New York, New York · Not yet recruiting

  • Investigator Site

    Cleveland, Ohio · Recruiting

  • Investigator Site

    Nashville, Tennessee · Not yet recruiting

  • Investigator Site

    Seattle, Washington · Recruiting

  • Investigator Site

    Anderlecht, Belgium · Not yet recruiting

  • Investigator Site

    Bonheiden, Belgium · Not yet recruiting

  • Investigator Site

    Ghent, Belgium · Not yet recruiting

  • Investigator Site

    Leuven, Belgium · Not yet recruiting

  • Investigator Site

    Liège, Belgium · Not yet recruiting

  • Investigator Site

    Ostend, Belgium · Not yet recruiting

  • Investigator Site

    Woluwe-Saint-Lambert, Belgium · Not yet recruiting

  • Investigator Site

    Milan, Italy · Not yet recruiting

  • Investigator Site

    Naples, Italy · Not yet recruiting

  • Investigator Site

    Pisa, Italy · Not yet recruiting

  • Investigator Site

    Amsterdam, Netherlands · Not yet recruiting

  • Investigator Site

    Barcelona, Spain · Not yet recruiting

  • Investigator Site

    L'Hospitalet de Llobregat, Spain · Not yet recruiting

  • Investigator Site

    Madrid, Spain · Not yet recruiting

  • Investigator Site

    Aberdeen, United Kingdom · Not yet recruiting

  • Investigator Site

    Cardiff, United Kingdom · Not yet recruiting

  • Investigator Site

    Glasgow, United Kingdom · Not yet recruiting

  • Investigator Site

    Leeds, United Kingdom · Not yet recruiting

  • Investigator Site

    London, United Kingdom · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.